Cancer patients in India are grappling with a critical shortage of two essential chemotherapy drugs, Cisplatin and Carboplatin, which are vital for treating several common cancers, including lung, ovarian, and breast cancer. Hospitals, including AIIMS Delhi and various private cancer centers, report dangerously low stocks, with some facilities having only one or two days' supply remaining. Medical professionals, such as Dr. Shyam Aggarwal from Sir Ganga Ram Hospital, express concern over the potential impact on treatment schedules, warning that delays could adversely affect patient outcomes. The shortage has persisted for approximately 40 days, with rising input costs for platinum-based drugs cited as a primary reason. Tarun Garg, from South Delhi Pharma, noted that some manufacturers have reduced or halted production due to price control issues, while others continue to export the drugs despite domestic needs. The lack of viable alternatives exacerbates the situation, making it imperative for authorities to address the crisis promptly to ensure that patients receive the necessary care.